Ulrike Gnad-Vogt
Corporate Officer/Principal chez CUREVAC N.V.
Fortune : 103 438 $ au 31/03/2024
Profil
Ulrike Gnad-Vogt is currently working as the Chief Medical Officer at CureVac SE since 2011.
Additionally, she holds the position of Senior Vice President & Head-Oncology at CureVac NV since 2011.
Dr. Gnad-Vogt obtained a doctorate degree from Universität des Saarlandes.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CUREVAC N.V.
0,02% | 31/03/2023 | 34 138 ( 0,02% ) | 103 438 $ | 31/03/2024 |
Postes actifs de Ulrike Gnad-Vogt
| Sociétés | Poste | Début |
|---|---|---|
| CUREVAC N.V. | Corporate Officer/Principal | 01/01/2019 |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Chief Tech/Sci/R&D Officer | 01/01/2011 |
Formation de Ulrike Gnad-Vogt
| Universität des Saarlandes | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CUREVAC N.V. | Health Technology |
| Entreprise privées | 1 |
|---|---|
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
